Zevra Therapeutics Dirección
Dirección controles de criterios 0/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Neil McFarlane
Chief Executive Officer (CEO)
US$3.4m
Compensación total
| Porcentaje del salario del CEO | 4.6% |
| Permanencia del CEO | 1.1yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 1.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
Nov 15
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Aug 30Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$90m |
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
Compensación vs. Mercado: La compensación total de Neil($USD3.45M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.18M).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Neil con los resultados de la empresa.
CEO
Neil McFarlane (51 yo)
1.1yrs
Permanencia
US$3,445,231
Compensación
Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He served as Independent Director at...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 1.1yrs | US$3.45m | sin datos | |
| Co-Founder & Chief Development Officer | no data | US$1.67m | 0.051% $ 248.5k | |
| CFO, Secretary & Treasurer | 9.4yrs | US$2.26m | 0.035% $ 168.6k | |
| Chief Commercial Officer & Executive VP of Business Development | 1.8yrs | US$1.82m | 0.0066% $ 32.0k | |
| Chief Scientific Officer | 1.8yrs | US$1.08m | 0.0051% $ 25.0k | |
| Vice President of Investor Relations & Corporate Communications | 2.3yrs | sin datos | sin datos | |
| Chief Legal Officer | less than a year | sin datos | sin datos | |
| Chief People Officer | less than a year | sin datos | sin datos | |
| Senior Vice President of Manufacturing | 1.8yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 1.8yrs | sin datos | sin datos | |
| Senior Vice President of Medical Affairs & Advocacy | 1.8yrs | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos |
1.8yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ZVRA no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 1.1yrs | US$3.45m | sin datos | |
| Independent Director | 1.6yrs | US$274.00k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$258.02k | 0% $ 0 | |
| Independent Chair | 3.3yrs | US$324.39k | 0.0014% $ 6.6k | |
| Member of Scientific and Medical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 1.6yrs | US$264.31k | 0.056% $ 273.9k | |
| Independent Director | 1.6yrs | US$260.67k | 0.0028% $ 13.7k | |
| Chairman of Scientific and Medical Advisory Board | 17.8yrs | sin datos | sin datos | |
| Member of Scientific & Medical Advisory Board | no data | sin datos | sin datos | |
| Co-Chair of Physician Advisory Council | 11.1yrs | sin datos | sin datos | |
| Co-Chair of Physician Advisory Council | 11.1yrs | sin datos | sin datos | |
| Independent Director | 1.3yrs | US$243.04k | 0.037% $ 182.6k |
1.6yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de ZVRA no se considera experimentada (1.6 años de permanencia promedio), lo que sugiere una nueva junta directiva.